<DOC>
	<DOCNO>NCT00000753</DOCNO>
	<brief_summary>To determine safety , toxicity , pharmacokinetic profile , antiretroviral activity atevirdine mesylate ( U-87201E ) HIV-infected patient . Per 06/04/93 amendment , also evaluate interactive effect didanosine ( ddI ) zalcitabine ( dideoxycytidine ; ddC ) zidovudine ( AZT ) pharmacokinetics U-87201E assess effect triple combination therapy immunologic virologic parameter . Since use non-nucleoside reverse transcriptase inhibitor U-87201E associate rapid development resistant HIV isolates , initial evaluation drug patient make combination AZT . Because inability detect resistance 6 week combine AZT/U-87201E therapy , protocol initially investigate U-87201E administer alone investigate effect drug AZT ddI ddC .</brief_summary>
	<brief_title>A Phase I Concentration-Targeted Multidose Study Atevirdine Mesylate ( U-87201E ) , AZT , ddI ddC</brief_title>
	<detailed_description>Since use non-nucleoside reverse transcriptase inhibitor U-87201E associate rapid development resistant HIV isolates , initial evaluation drug patient make combination AZT . Because inability detect resistance 6 week combine AZT/U-87201E therapy , protocol initially investigate U-87201E administer alone investigate effect drug AZT ddI ddC . Ten patient treat three target concentration range U-87201E . Patients second cohort enrol immediately patient first cohort accrue ; patient third cohort enrol 5 10 patient second cohort tolerate dose least 4 week . The MTD dose produce dose-limiting grade 3 4 toxicity five 10 patient . At least two woman five antiretroviral naive patient must enrol dose concentration range . Patients receive least 8 week monotherapy U-87201E , possible extension least 24 week dose U-87201E alone combination zidovudine plus either ddI ddC . Patients follow weekly least 8 week , applicable , week 10 , 12 , 16 , 20 , 24 monthly thereafter , 1 month follow last dose . Patients combination therapy indwell venous catheter insert first 2 day combination therapy . Per 10/15/93 amendment , MTD establish first three cohort , 10 additional patient enrol fourth concentration .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Didanosine</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<mesh_term>Zalcitabine</mesh_term>
	<mesh_term>Atevirdine</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed : PCP prophylaxis pentamidine , TMP/SMX , dapsone ( appropriate ) . Clotrimazole troche nystatin oral suspension oral candidiasis . Acyclovir ( 1000 mg/day ) herpes lesion . Supportive care deem necessary toxicity . Patients must : HIV infection . CD4 count &lt; = 500 cells/mm3 . No active opportunistic infection . Consent parent , guardian , person power attorney , less 18 year age . NOTE : Participation woman study encourage . Exclusion Criteria Coexisting Condition : Patients follow symptoms condition exclude : Acute medical problem , include opportunistic infection ( e.g. , active cryptococcosis , Pneumocystis carinii , herpes zoster , histoplasmosis , CMV ) nonopportunistic disease ( e.g. , liver renal disease lymphoma ) . Current diagnosis malignancy systemic therapy would require study . Active gastrointestinal disorder . Concurrent Medication : Excluded : Investigational drug . Systemic therapy malignancy . Phenobarbital , phenytoin , ketoconazole , rifampin , rifabutin , cimetidine , beta blocker , chronic antacid , antiarrhythmic agent , medication know affect cardiac conduction seizure threshold . Patients follow prior condition exclude : History cardiovascular disease , include conduction disturbance , arrhythmias atherosclerotic heart disease . History CNS disease seizure disorder , AIDS Dementia Complex , progressive multifocal leukoencephalopathy , active neurological disorder . History chronic gastrointestinal disorder chronic diarrhea ( &gt; 4 week duration ) . Prior Medication : Excluded : Antiretroviral immunomodulator agent ( AZT , ddI , ddC , interferon , etc . ) within 15 day prior study entry . Cytotoxic chemotherapy within 1 month prior study entry . Prior U87201E nonnucleoside reverse transcriptase inhibitor ( i.e. , nevirapine , TIBO , L697,661 ) . Present use alcohol illicit drug .</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Zalcitabine</keyword>
	<keyword>Didanosine</keyword>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>AIDS-Related Complex</keyword>
	<keyword>Antiviral Agents</keyword>
	<keyword>Zidovudine</keyword>
</DOC>